Fluorotryptophane

Fluorotryptophane

SCHEMBL249955

N[C@H](Cc1c[nH]c2ccc(F)cc12)C(=O)O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.73
KMT2A Q03164 4/20 0.73
TSHR P16473 3/20 0.73
SLC6A4 P31645 3/20 0.73
KDM4E B2RXH2 2/20 0.73
LMNA P02545 2/20 0.73
MAPT P10636 2/20 0.73
HTR2C P28335 2/20 0.73
BLM P54132 2/20 0.73
PMP22 Q01453 2/20 0.73
HTR1A P08908 2/20 0.73
ALDH1A1 P00352 1/20 0.73
CYP3A4 P08684 1/20 0.73
ADORA3 P0DMS8 1/20 0.73
ALOX15 P16050 1/20 0.73
NFKB1 P19838 1/20 0.73
HTR7 P34969 1/20 0.73
HTR2B P41595 1/20 0.73
MTOR P42345 1/20 0.73
NPSR1 Q6W5P4 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorotryptophane SCHEMBL125000 1.00 HTR2A (0.73) HTR2AKMT2ATSHRSLC6A4KDM4E
Fluorotryptophane SCHEMBL29623254 1.00 HTR2A (0.73) HTR2AKMT2ATSHRSLC6A4KDM4E
Fluorotryptophane SCHEMBL29623154 1.00 HTR2A (0.73) HTR2AKMT2ATSHRSLC6A4KDM4E
Fluorotryptophane SCHEMBL29358068 1.00 HTR2A (0.73) HTR2AKMT2ATSHRSLC6A4KDM4E
Fluorotryptophane SCHEMBL122142 1.00 HTR2A (0.73) HTR2AKMT2ATSHRSLC6A4KDM4E
Fluorotryptophane SCHEMBL18301531 0.94 KMT2A (0.78) HTR2AKMT2ATSHRSLC6A4KDM4E
Fluorotryptophane SCHEMBL18301535 0.94 KMT2A (0.78) HTR2AKMT2ATSHRSLC6A4KDM4E
SCHEMBL248870 0.89 KMT2A (0.66) HTR2AKMT2ATSHRSLC6A4KDM4E
SCHEMBL2330930 0.89 KMT2A (0.66) HTR2AKMT2ATSHRSLC6A4KDM4E
SCHEMBL7331236 0.89 HTR2A (0.66) HTR2AKMT2ATSHRSLC6A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108315370-A A kind of preparation method of halogen tryptophan 滨海吉尔多肽有限公司 2018-07-24 CN claimed
EP-0017760-B1 SOMATOSTATIN ANALOG PEPTIDES, THEIR PREPARATION AND USE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION CIBA-GEIGY AG (CH) 1983-05-11 EP claimed
US-4316890-A Peptides and processes for the manufacture thereof CIBA-GEIGY CORPORATION (US) 1982-02-23 US claimed
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
CN-106188239-B Potent compstatin analogs 宾夕法尼亚州大学理事会 2020-01-07 CN disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed
US-20190016758-A1 Potent Compstatin Analogs THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2019-01-17 US disclosed
EP-3363810-A1 POTENT COMPSTATIN ANALOGS The Trustees Of The University Of Pennsylvania (US) 2018-08-22 EP disclosed
CN-108315370-A A kind of preparation method of halogen tryptophan 滨海吉尔多肽有限公司 2018-07-24 CN disclosed
EP-2377877-B1 Potent compstatin analogs UNIV PENNSYLVANIA (US) 2018-03-28 EP disclosed
EP-2377878-B1 Potent compstatin analogs UNIV PENNSYLVANIA (US) 2018-03-28 EP disclosed
EP-1392317-A4 SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF ANTEXPHARMA INC (US) 2005-10-19 EP disclosed
EP-1392317-A2 SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF Antexpharma, Inc. (US) 2004-03-03 EP disclosed
WO-2002100327-A2 SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF ANTEXPHARMA, INC. (US) 2002-12-19 WO disclosed
US-4603120-A ANTIDIZBETIC, HEMOSATATIC, SOMATOSTATIN ANALOGS CIBA-GEIGY CORPORATION (US) 1986-07-29 US disclosed
US-4358439-A ANTIDIABETIC AGENT AND/OR GASTROINTESTINAL BLEEDING CIBA-GEIGY CORPORATION (US) 1982-11-09 US disclosed
EP-0001295-B1 SOMATOSTATIN-LIKE CYCLOPEPTIDES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR THERAPEUTICAL APPLICATION CIBA-GEIGY AG (CH) 1982-03-17 EP disclosed
US-4316890-A Peptides and processes for the manufacture thereof CIBA-GEIGY CORPORATION (US) 1982-02-23 US disclosed
US-4238481-A HYPOGLYCEMIC AGENT; HYPERGLYCEMIC AGENT; ANIMAL GROWTH REGULATOR CIBA-GEIGY CORPORATION (US) 1980-12-09 US disclosed
EP-0001295-A2 Somatostatin-like cyclopeptides, a process for their preparation, pharmaceutical compositions containing them, and their therapeutical application CIBA-GEIGY AG (CH) 1979-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039846-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 HTR2A 3134/4885KMT2A 2510/4885TSHR 2337/4885
US-20190263802-A1 COMPOUNDS AND METHOD OF USE AIFM2, GPX4, GPX1 HTR2A 3059/4885KMT2A 2475/4885TSHR 2183/4885
US-20190016758-A1 Potent Compstatin Analogs C3AR1, C9, C1QBP HTR2A 3106/4885KMT2A 4236/4885TSHR 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.